為了準備衍生物分子庫的溶液，我們應用目前常用的簡單方法，快速多樣性導向amide forming反應。這些化合物透過5’-amino-uridine和24種carboxylic acid之間的耦合反應被合成出來，接著在沒有生成物純化的情況下，直接進行細胞毒性分析。我們希望這個新發展中的方法可以針對癌症治療篩選出有潛力的藥物。人類非小細胞肺腫瘤細胞A549是我們當作目標的選擇。為了排除溶劑DMF對於A549的毒性，被採用策略是藉由加入鹽酸使DMF變成一個四級胺鹽。雖然這樣處理克服DMF的毒性，但是結果是A549生長在pH=4與pH=5之間的異常生理狀態。因此，MTT分析在這個狀況之下沒有辦法被實行而且利用我們藉由全光譜分析了這些原因。細胞存活率只能以顯微鏡觀察紀錄下來。更幸運的是，被使用的試劑似乎對於A549沒有毒性。最後，在24種溶液當做藥物被加入含有A549的96孔盤之中，我們沒有發現任何一個具有明顯細胞毒性。在我們粗略地完成一些試驗之後，仍然有許多的問題和困難必須被克服而且使整個實驗的概念更理想化。

We apply a current simple method, quick diversity-oriented amide-forming reaction, for preparation in solution of a library of compounds. These compounds are synthesized through a coupling reaction between a 5’-amino uridine and 24 kinds of carboxylic acids, followd by a direct assay of cytotoxicity without product purification. We hope that this innovative developing approach can screen potential drugs for cancer therapy. The human non-small cell lung tumor cell A549 is our choice as a targer. In order to eliminate the toxicity of solvent DMF (dimethylformamide) to A549, one strategy adopted is to make DMF become a quaternary salt by adding HCl. Althoughg this treatment overcomes the toxicity of DMF, the effect is the abnormal physiological condition where A549 growing is between pH=4 and pH=5. Therefore, MTT assay isn’t carried out under this condition, and we analyze the reasons by full spectrum. The cell viability is recorded only with microscopic observation. More fortunately, the reagents used seem not to be toxic to A549. Finally, among the 24 kinds of solutions as drugs added into 96-well plate containing A549, we don’t find out anyone possessing apparent cytotoxicity. After we roughly completed these tests, there are still many problems and difficulties have to be overcomed and make the whole experimental concept more optimized.

文獻資料
(1) Mathews, V. H., Ahern., Biochemistry. third edition. 2000. 815.
(2) Seok Rye Choi, Z.-P. Z., Ann-Marie Chacko, Paul D. Acton, Juri Tjuvajev-Gelovani, Mikhai Doubrovin, MD, David C. K. Chu, Hank F. Kung, Acad. Radiol. 2005,12, 7, 798-805.
(3) Ogino, T., Otsuka, T., and Takahashi, M., J. Virol. 1997, 21, 1232–1235.
(4) Balasubramanian, N. K., Veerisetty, V., Gentry, G.A., J. Gen. Virol. 71, 2979–2987.
(5) Cheng, Y.-C., and M. Ostrander., J. Biol. Chem. 1976, 251, 2605–2610.
(6) Lee, C. G., C. G. Kim, R. Namkung, S. E. Lee, and S. D. Park., Cytotechnology 1990, 3, 141–147.
(7) Haarr, L., and T. Flatmark., J. Gen. Virol. 1987, 68:2817–2829.
(8) Shiraki, K., T. Ogino, K. Yamanishi, and M. Takahashi., J. Gen. Virol. 1985, 66, 221–229.
(9) Bart Degreve, M. J., Erik De Clercq, Anna Karl Sson; Balzarini, a. J., J. Virol. 1998, 9535–9543.
(10) Barba, D., Hardin, J., Ray, J., and Gage, F. H., J. Neurosurg. 1993, 79, 729–735.
(11) Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D., Proc. Natl. Acad. Sci. USA 1993, 90, 7024–7028.
(12) Culver, K. W., Ram, Z., Walbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M., Science 1992, 256, 1550–1552.
(13) Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and Breakefield, X. O., New Biol. 1991, 3, 608–614.
(14) Moolten, F. L., and Wells, J. M., J. Natl. Cancer Inst. 1990, 82, 297–300.
(15) Drake, R. R., Wilbert, T. N., Hinds, T. A., and Gilbert, K., J. Biol. Chem. 1999, 274, 37186–37192.
(16) Wiebe LI., M. K., and Knaus EE., Q. J. Nucl. Med. 1997, 41, 79–89.
(17) Rubsam, L. Z., Davidson, B. L., and Shewach, D. S., Cancer Res. 1998, 58, 3873–3882.
(18) Halloran, P. J., and Fenton, R. G., Cancer Res. 1998, 58, 3855–3865.
(19) Erik F. J. De Vries, A. R. B., Geke A.P. Hospers, Nanno H. Mulder, and Willem Vaalburg, Current Pharmaceutical Design. 2002, 8, 1435-1450.
(20) Balzarini J, B. C., De Clercq E., J. Biol. Chem. 1993, 268, 6332–6337.
(21) Balzarini J, B. C., Walker RT, De Clercq E., Mol. Pharmacol. 1994, 45, 1253–1258.
(22) Balzarini J., B. C., Walker RT, De Clercq E., Gene Ther. 1995, 2, 317–322.
(23) Balzarini, J. D., B; Andrei, G; Neyts, J; Sandvold, M; Myhren, F; de Clercq, E., Gene Ther. 1998, 5, 419–426.
(24) Degrève, B. A., G; Izquierdo, M; Piette, J; Morin, K; Knaus, E E; Wiebe, L I; Basrah, I; Walker, R T; De Clercq, E; Balzarini, J., Gene Ther. 1997, 4, 1107–1114.
(25) Short, M. P., Choi, B. C., Lee, J. K., Malick, A., Breakefield, X. O., and Martuza, R. L., J. Neurosci. Res. 1990, 27, 427–439.
(26) Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N., Cancer Res. 1993, 53, 5274–5283.
(27) Freeman, S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A., Semin. Oncol. 1996, 23, 31–45.
(28) Denning, C., and Pitts, J. D., Hum. Gene Ther. 1997, 8, 1825–1835.
(29) Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J., Hum. Gene. Ther. 1993, 4, 725–731.
(30) Kato, K., Yoshida, J., Mizuno, M., Sugita, K., and Emi, N., Neurol. Med. Chir. (Tokyo) 1994, 34, 339–344.
(31) Wu, J. K., Cano, W. G., Meylaerts, S. A., Qi, P., Vrionis, F., and Cherington, V., Neurosurgery 1994, 35, 1094–1102.
(32) Boucher, P. D., Ruch, R. J., and Shewach, D. S., Hum. Gene Ther. 1998, 9, 801–814.
(33) McMasters, R. A. W., Tasha N; Jones, Kelly E; Pitlyk, Karen; Saylors, Robert L; Moyer, Mary Pat; Chambers, Timothy C; Drake, Richard R., Cancer Gene Ther. 2000, 7, 563–573.
(34) Ishii-Morita, H. A., R; Mullen, C A; Hirano, H; Koeplin, D A; Ram, Z; Oldfield, E H; Johns, D G; Blaese, R M., Gene Ther. 1997, 4, 244–251.
(35) Bart Degreve, M. J., Erik De Clercq, and Jan Balzarini, Academic Radiology 2005, 12, 7, 798-805.
(36) Steel, K. P., Nature Genetics 1998, 20, 319 - 320.
(37) Colombo, B. M., Benedetti, S., Ottolenghi, S., Mora, M., Pollo, B., Poli, G., and Finocchiaro, G., Hum. Gene Ther. 1996, 6, 763–772.
(38) Altered gap junctional communication, intercellular signaling, and growth in cultured astrocytes deficient in connexin43.; Naus, C. C., Bechberger, J. F., Zhang, Y., Venance, L., Yamasaki, H., Juneja, S. C., Kidder, G. M., and Giaume, C., Ed.; Vol. J. Neurosci. Res. 1997, 49, 528–540.
(39) Yamasaki, H., Mutat. Res. 1996, 365, 91–105.
(40) Cirenei, N., Colombo, B. M., Mesnil, M., Benedetti, B., Yamasaki, H., and Finocchiaro, G., Gene Ther. 1998, 5, 1221–1226.
(41) Shinoura, N., Chen, L., Wani, M. A., Kim, Y. G., Larson, J. J., Warnick, R. E., Simon, M., Menon, A. G., Bi, W. L., and Stambrook, P. J., J. Neurosurg. 1996, 84, 839–845.
(42) Zhu, D., Caveney, S., Kidder, G. M., and Naus, C. C., Proc. Natl. Acad. Sci. USA 1991, 88, 1883–1887.
(43) Dilber, M. S., Abedi, M. R., Christensson, B., Bjorkstrand, B., Kidder, G. M., Naus, C. C., Gahrton, G., and Smith, C. I., Cancer Res. 1997, 57, 1523–1528.
(44) Duflot-Dancer, A., Mesnil, M., and Yamasaki, H., Oncogene 1997, 15, 2151–2158.
(45) Mesnil, M., Piccoli, C., and Yamasaki, H., Cancer Res. 1997, 57, 2929–2932.
(46) Vrionis, F. D., Wu, J. K., Qi, P., Waltzman, M., Cherington, V., and Spray, D. C., Gene Ther. 1997, 4, 577–585.
(47) Touraine, R. L., Vahanian, N., Ramsey, W. J., and Blaese, R. M., Hum. Gene Ther. 1998, 9, 2385–2391.
(48) T., H., Nat Med. 2000, 6, 6.
(49) Ghoumari, A. M., Rixe, O., Yarovoi, S. V., Zerrouqi, A., Mouawad, R., Poynard, T., Opolon, P., Khayat, D., and Soubrane, C., Gene Ther. 1996, 3, 483–490.
(50) Tjuvajev JG., F. R., Watanabe K., Joshi R., Oku T., Kennedy J., Beattie B., Koutcher J., Larson S., and Blasberg RG., Cancer Res. 1996, 56, 4087–4095.
(51) Gambhir SS., B. J., Wu L., Iyer M., Namavari M., Satyamurthy N., Bauer E., Parrish C., MacLaren DC., Borghei AR., Green LA., Sharfstein S., Berk AJ., Cherry SR., Phelps ME., and Herschman HR., J. Nucl. Med. 1998, 39, 2003–2011.
(52) Haberkorn U., A. A., Morr I., Knopf KW., Germann C., Haeckel R., Oberdorfer F., and van Kaick G., J. Nucl. Med. 1997, 38, 287–294.
(53) Germann C., S. A., Grierson JR., Morr I, and Haberkorn U., Nucl. Med. 1998, 39, 1418–1423.
(54) JM., C., Antiviral Res. 1996, 29, 125–139.
(55) M., G., N. Engl. J. Med. 1996, 334, 1136–1138.
(56) Haubner R., A. N., Hantzopoulos PA., Gansbacher B., and Schwaiger M., Eur. J. Nucl. Med. 2000, 27, 283–291.
(57) Juri Gelovani Tjuvajev, M. D., Timoyhy Akhurst; Shangde Cai, J. B., Mian M. Alauddin, Ronald Finn; William Bornmann, H. T., Peter S. Conti, Ronald G.; Blasberg, J. Nucl. Med. 2002, 43, 1072-1083.
(58) C.-Y. Wu, C.-F. C., J. S.-Y. Chen, C.-H. Wong, C.-H. Lin, Angew. Chem. 2003, 115, 4809 -4812.
(59) A. Brik, Y.-C. L., J. Elder, C.-H. Wong, Chemistry & Biology, 2002, 9, 891–896.
(60) Michael D. Best, A. B., Eli Chapman, Lac V. Lee, Wei-Chieh Cheng, and Chi-Huey Wong, ChemBioChem 2004, 5, 811 - 819.
(61) Bertozzi, K. A. W. a. C. R., Chemistry & Biology, 2002, 9, 113–129.
(62) E. Giovannetti et al., Mol Pharmacol. 2005, 68, 110-118.
(63) D., T. I. a. R., Cancer Res. 1989, 49(16), 4373-4384.
(64) Kallinowski F. et al., Cancer Res. 1988, 7264-72.
(65) Martinez-Zaguilan R, S. E., Seftor RE, Chu YW, Gillies RJ, Hendrix MJ., Clin. Exp. Metastasis. 1996 14(2), 176-186.
(66) Gerweck LE, V. S., Kozin S., Mol. Cancer Ther. 2006, 5(5),1275-1279.